Market Chatter: CSL Doesn't 'Expect Any Material Impact' from US Pharmaceutical Tariffs, The Australian Says

MT Newswires Live

Sep 26

CSL (ASX:CSL) says it does not "expect any material impact" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.

The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.

The firm has a "very significant US manufacturing footprint," the spokesperson added.

It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2570079986"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570079986\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570079986?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570079986","market":"hk","top_or_hot":-1,"title":"Market Chatter: CSL Doesn't 'Expect Any Material Impact' from US Pharmaceutical Tariffs, The Australian Says","media":"MT Newswires Live","content":"<html><body><p> CSL (ASX:CSL) says it does not \"expect any material impact\" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.</p><p>The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.</p><p>The firm has a \"very significant US manufacturing footprint,\" the spokesperson added.</p><p>It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: CSL Doesn't 'Expect Any Material Impact' from US Pharmaceutical Tariffs, The Australian Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: CSL Doesn't 'Expect Any Material Impact' from US Pharmaceutical Tariffs, The Australian Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-26 14:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CSL (ASX:CSL) says it does not \"expect any material impact\" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.</p><p>The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.</p><p>The firm has a \"very significant US manufacturing footprint,\" the spokesperson added.</p><p>It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2570079986","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570079986","pubTimestamp":1758866697,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CSL  says it does not \"expect any material impact\" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.The firm has a \"very significant US manufacturing footprint,\" the spokesperson added.It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","BK7067":"生物科技","XJO.AU":"标普/澳交所 200指数","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK7508":"医药生物股","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","BK7511":"ESG概念","BK7501":"新冠治疗股","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","XKO.AU":"标普/澳交所 300指数","CSL.AU":"CSL LIMITED","XAO.AU":"标普/澳交所 普通股指数","BK4086":"建筑产品"},"translate_title":"市场热议：《澳大利亚人报》表示，CSL“预计美国药品关税不会产生任何重大影响”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XAO.AU":1.5,"CSL":1.5,"XJO.AU":1.5,"XKO.AU":1.5,"CSL.AU":1.5},"content_text":"CSL (ASX:CSL) says it does not \"expect any material impact\" from the new US pharmaceutical tariff regime, The Australian reported Friday, citing a company spokesperson.The US administration said it would impose a 100% tariff on imports of branded or patented pharmaceutical products, effective Oct. 1, unless the company is constructing a manufacturing plant in the US.The firm has a \"very significant US manufacturing footprint,\" the spokesperson added.It is expanding its US capabilities to meet demand for its therapies, and it will monitor further pronouncements from the administration in relation to the details of the tariffs.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}